Denosumab is a human monoclonal antibody that binds to RANKL, the principal mediator of osteoclastic bone resorption ([Figure By inhibiting the action of RANKL, denosumab causes a reduction in the differentiation, activity, and survival of osteoclasts, leading to lower rates of bone resorption.[@b80-jep-2-121] It is given subcutaneously at a dose of 60 mg every six months. Denosumab has been proposed to have several advantages over bisphosphonate therapy, including the potential for increased compliance due to less frequent and easier administration (subcutaneous injection vs intravenous for zoledronic acid) with potentially fewer side effects.[@b81-jep-2-121]
Denosumab is a human monoclonal antibody that targets RANKL, the primary mediator of osteoclast-driven bone resorption. By inhibiting RANKL, it reduces the differentiation, activity, and survival of osteoclasts, thereby decreasing bone resorption. Administered subcutaneously at a dose of 60 mg every six months, denosumab offers potential advantages over bisphosphonate therapy, such as improved compliance due to less frequent and simpler administration (subcutaneous injection compared to intravenous zoledronic acid) and potentially fewer side effects.
Denosumab is a human monoclonal antibody that targets RANKL, a key factor in the process of osteoclastic bone resorption. By inhibiting RANKL, denosumab reduces the differentiation, activity, and survival of osteoclasts, which results in decreased bone resorption. The medication is administered subcutaneously at a dosage of 60 mg every six months. Denosumab is considered to have various advantages over bisphosphonate therapy, such as potentially higher patient compliance due to its less frequent and simpler administration method compared to intravenous options like zoledronic acid, along with a possibility of having fewer side effects.
Denosumab is a human monoclonal antibody against RANKL, which is involved in osteoclastic bone resorption. Denosumab inhibits RANKL, which inhibits osteoclast differentiation, activity, and survival, leading to reduced bone resorption. The drug is given subcutaneously at 60 mg every 6 months. Denosumab is thought to have several benefits over bisphosphonate therapy, including a potential increase in patient compliance because it is administered less often and in a more convenient manner than intravenous agents such as zoledronic acid, and a potential reduction in side effects.
Denosumab is a human monoclonal antibody that binds to RANKL, an important mediator of osteoclastic bone resorption. Denosumab inhibits RANKL, which leads to reduced differentiation, activity, and survival of osteoclasts, and consequently, reduced bone resorption. The drug is given subcutaneously at a dose of 60 mg every 6 months. Denosumab is thought to have several benefits over bisphosphonate therapy, including possibly greater patient compliance because of its less frequent and easier administration compared to intravenous agents such as zoledronic acid, and possibly fewer side effects.